Skip to content

Mucoadhesive Film With/without Acmella Oleracea & Triamcinolone Acetonide for Aphthous Ulcers

Comparison of the Efficacy of Mucoadhesive Film with and Without Acmella Oleracea Extract and 0.1% Triamcinolone Acetonide for Treatment of Aphthous Ulcers: a Randomized Control Trial

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06622213
Enrollment
72
Registered
2024-10-02
Start date
2024-10-15
Completion date
2026-05-31
Last updated
2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphthous Stomatitis

Keywords

Oral ulcer

Brief summary

The purpose of this study is to evaluate the effectiveness of mucoadhesive film with or without Acmella oleracea extract compared to standard treatment by using 0.1% triamcinolone acetonide in pain relief, promoting wound healing, healing time and satisfaction in 3 aspects included taste, product used and quality of life after using the product.

Detailed description

Participants who consent and meet the inclusion criteria will be allocated into 3 groups using block randomization: group 1: mucoadhesive film with Acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without Acmella oleracea extract.

Interventions

OTHERmucoadhesive film with Acmella oleracea extract

Apply 1 patch on ulcer 3 times per day (after meals)

Apply ¼ inch on ulcer 3 times per day (after meals)

Apply 1 patch on ulcer 3 times per day (after meals)

Sponsors

National Institute of Dental and Craniofacial Research (NIDCR)
CollaboratorNIH
Khon Kaen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessor will not know which treatment each participant will receive (single blinding). Participants will know the type of treatment they received.

Intervention model description

group 1: mucoadhesive film with Acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without Acmella oleracea extract.

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy participants aged 18-50 years without any underlying diseases. 2. Participants are voluntary and have signed the informed consent. 3. Participants are literate. 4. Participants can follow the treatment guidelines and follow up. 5. Participants have one untreated oral ulcer lesion. * An ulcer has occurred within 48 hours. * The ulcer size is less than 10 mm. * The ulcer is clearly visible and located on non-keratinized oral mucosa such as buccal mucosa, labial mucosa, alveolar mucosa, or buccal vestibule. * The ulcer must be painful. 6. If an ulcer is caused by a denture or orthodontic appliance, the cause must be eliminated before participation. 7. Participants must not be currently participating in any other clinical studies about oral ulcer

Exclusion criteria

1. Participants with allergies to herbal extracts, Acmella oleracea, or steroids. 2. Participants with chronic underlying diseases. 3. Participants with underlying diseases that may affect wound healing. 4. Participants receiving anti-analgesic drug, systemic steroids, antibiotics, hormones, NSAIDS, or any drugs that affect the oral mucosa. 5. Oral ulcer lesion larger than 10 mm or lesions resembling herpetic form of aphthous ulcers. 6. Oral ulcers are caused by infection or associated with systemic diseases. 7. Participants with poor oral hygiene requiring emergency treatment. 8. Participants who smoke or consume alcohol regularly. 9. Participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

Design outcomes

Primary

MeasureTime frameDescription
Reduction of ulcer size after using productBase line, day4, day7, day10 and day 14Reduction of ulcer size will be evaluated by measuring the diameter of ulcers size using a periodontal probe and photograph on the first day and each follow up visit.
Pain scoreBase line, day4, day7, day10 and day 14The pain score will be assessed by using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from "no pain"(0) to "worst pain" (10).The pain level will be recorded on the first day. The participants will then reassess their pain score again after receiving the intervention, which will be evaluated at each follow up visit.

Secondary

MeasureTime frameDescription
Satisfaction scoreDay 14Participants' satisfaction after using product will be assessed using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from "unsatisfied" (0) to "most satisfied" (10). Satisfaction will be evaluated on the last day of follow-up.
Quality of life scorebase line and day 14Oral health impact on quality of life will be evaluated using the Thai version of the Oral Health Impact Profile-14 (OHIP-14). The survey classified into 7 dimensions with 2 items per dimension included functional limitation, painful, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Participants must choose the answer based on the frequency of problem occurrence. The frequency level is divided into 5 level: never= 0 point, rarely = 1 point, sometimes = 2 points, often = 3 points, always = 4 points. Total scores in each person range are between 0 to 56 points.The quality of life will be survey on the first and the last day of follow-up.

Contacts

Primary ContactKemporn Kitsahawong, Ph.D
kkempo@kku.ac.th(+66)91-4442699
Backup ContactPorntip Phajongviriyatorn, MsC.
ppornt@kku.ac.th(+66)86-7165260

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026